{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    42,
    43,
    44,
    46,
    47,
    48,
    49,
    50,
    51,
    52,
    53,
    54,
    55,
    56,
    58,
    62,
    63,
    64,
    67,
    71,
    72,
    73,
    79,
    80,
    93,
    98,
    121
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "first administration of study drug"
      },
      {
        "id": "anchor_2",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "baseline assessment"
      },
      {
        "id": "anchor_4",
        "definition": "Day 1 of Cycle 1",
        "anchorType": "CycleStart",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Cycle 1, \nDay 1"
      },
      {
        "id": "anchor_3",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "informed consent"
      },
      {
        "id": "anchor_5",
        "definition": "procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_2",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_3",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_cycle_1",
        "type": "Cycle",
        "cycleLength": "P2D",
        "exitCondition": "Unacceptable toxicity",
        "sourceText": "2-week \ncycle"
      },
      {
        "id": "rep_cycle_2",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until disease progression"
      },
      {
        "id": "rep_cycle_5",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until disease\nprogression"
      },
      {
        "id": "rep_cycle_8",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until disease \nprogression"
      },
      {
        "id": "rep_cycle_12",
        "type": "Cycle",
        "sourceText": "until \ndiscontinuation"
      },
      {
        "id": "rep_cycle_13",
        "type": "Cycle",
        "sourceText": "until discontinuation"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "Screening Phase"
      },
      {
        "id": "rep_window_4",
        "type": "Continuous",
        "sourceText": "Screening \nPhase"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "Treatment Phase"
      },
      {
        "id": "rep_window_11",
        "type": "Continuous",
        "sourceText": "Treatment \nPhase"
      },
      {
        "id": "rep_window_17",
        "type": "Continuous",
        "sourceText": "Treatment Period"
      },
      {
        "id": "rep_window_21",
        "type": "Continuous",
        "sourceText": "Follow-Up Phase"
      },
      {
        "id": "rep_window_23",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_window_24",
        "type": "Continuous",
        "sourceText": "Follow-up \nphase"
      },
      {
        "id": "rep_window_26",
        "type": "Continuous",
        "sourceText": "Follow-up Phase"
      },
      {
        "id": "rep_window_29",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_window_31",
        "type": "Continuous",
        "sourceText": "30 days before"
      },
      {
        "id": "rep_window_32",
        "type": "Continuous",
        "sourceText": "60 days before"
      },
      {
        "id": "rep_window_33",
        "type": "Continuous",
        "sourceText": "7 days pre"
      },
      {
        "id": "rep_window_34",
        "type": "Continuous",
        "sourceText": "30 days \nafter"
      },
      {
        "id": "rep_window_35",
        "type": "Continuous",
        "sourceText": "30 \ndays after"
      },
      {
        "id": "rep_window_41",
        "type": "Continuous",
        "sourceText": "72 hours after"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P0D",
        "interval": "P28D",
        "minObservations": 1,
        "exitCondition": "Disease progression or unacceptable toxicity",
        "sourceText": "repeat every 28 days"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "epoch_1",
          "epoch_2",
          "epoch_3",
          "epoch_4",
          "epoch_5",
          "epoch_6"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Required Assessment",
          "End of Study",
          "End of Treatment Visit",
          "Day 1",
          "Safety Follow-up Visit",
          "Cycle 1 Day 1"
        ],
        "sourceText": "[{'condition': 'Subject experiences disease progression (PD)', 'path': ['DISCONTINUE_STUDY_TREATMENT', 'POST_PROGRESSION_SURVIVAL_FOLLOW_UP']}, {'condition': 'Subject experiences adverse event (AE) requiring discontinuation', 'path': ['EARLY_TERMINATION_VISIT', 'SAFETY_FOLLOW_UP', 'EFFICACY_FOLLOW_UP']}, {'condition': 'Subject requires dose modification for hepatic impairment', 'path': ['DOSE_REDUCTION', 'CONTINUED_TREATMENT']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Recurring",
        "rationale": "SINGLE signals: 1; RECURRING signals: 2"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "SINGLE signals: 4"
      },
      {
        "activityId": "Ecg",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Event",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1; SINGLE signals: 1"
      },
      {
        "activityId": "Laboratory Assessments",
        "executionType": "Recurring",
        "rationale": "SINGLE signals: 5; RECURRING signals: 10"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Drug Administration",
        "executionType": "Single",
        "rationale": "SINGLE signals: 4"
      },
      {
        "activityId": "Mri",
        "executionType": "Single",
        "rationale": "SINGLE signals: 7"
      },
      {
        "activityId": "Biopsy",
        "executionType": "Single",
        "rationale": "SINGLE signals: 7; RECURRING signals: 2"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Recurring",
        "rationale": "SINGLE signals: 3; RECURRING signals: 4"
      },
      {
        "activityId": "Screening Assessment",
        "executionType": "Single",
        "rationale": "The protocol indicates a screening phase to determine eligibility prior to randomization, occurring once per subject."
      },
      {
        "activityId": "Clinical Efficacy Assessment",
        "executionType": "Single",
        "rationale": "Efficacy is monitored at scheduled intervals throughout the Phase 3 study to compare treatment arms."
      },
      {
        "activityId": "Safety Monitoring (Adverse Events)",
        "executionType": "Single",
        "rationale": "Safety data and adverse events are collected continuously from the time of first dose through the follow-up period."
      },
      {
        "activityId": "Pharmacokinetic (PK) Sampling",
        "executionType": "Single",
        "rationale": "PK data collection typically involves multiple blood draws over a specific time window following drug administration."
      },
      {
        "activityId": "Dose Modification for Toxicity",
        "executionType": "Single",
        "rationale": "Adjustments to ibrutinib or BR dosage are conditional workflows triggered by specific clinical toxicity grades or events."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "procedure_conditional",
        "text": "a. Assessments/procedures should be completed on the day indicated in the Time and Events Schedule",
        "footnoteId": "fn_1",
        "structuredCondition": "procedure.date == schedule.indicated_day",
        "appliesToActivityIds": [
          "All Assessments",
          "All Procedures"
        ],
        "sourceText": "a. Assessments/procedures should be completed on the day indicated in the Time and Events Schedule"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_before",
        "text": "b. Results of tests obtained prior to signing the informed consent conducted as part of the subject's standard care may be used",
        "footnoteId": "fn_2",
        "structuredCondition": "test_results.source == 'standard_care' && test_results.date < informed_consent.date",
        "appliesToActivityIds": [
          "Screening Tests"
        ],
        "sourceText": "b. Results of tests obtained prior to signing the informed consent conducted as part of the subject'"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "c. For Day 1, Cycle 1, clinical laboratory tests do not need to be repeated if Screening tests were performed within 5 days",
        "footnoteId": "fn_3",
        "structuredCondition": "if(screening_labs.date >= (day_1_cycle_1.date - P5D)) { repeat_labs = false }",
        "appliesToActivityIds": [
          "Clinical laboratory tests"
        ],
        "sourceText": "c. For Day 1, Cycle 1, clinical laboratory tests do not need to be repeated if Screening tests were "
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_before",
        "text": "d. During the Treatment Phase, clinical laboratory samples may be obtained on the day of or day prior to dosing",
        "footnoteId": "fn_4",
        "structuredCondition": "sample_collection.date.range(dosing.date - P1D, dosing.date)",
        "appliesToActivityIds": [
          "Clinical laboratory samples"
        ],
        "sourceText": "d. During the Treatment Phase, clinical laboratory samples may be obtained on the day of or day prio"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "y. Notification of progressive disease and supportive clinical results must be sent within 24 hours to the sponsor",
        "footnoteId": "fn_5",
        "structuredCondition": "notification.send(sponsor) <= progressive_disease_event + PT24H",
        "appliesToActivityIds": [
          "Notification of progressive disease",
          "Supportive clinical results"
        ],
        "sourceText": "y. Notification of progressive disease and supportive clinical results must be sent within 24 hours "
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_after",
        "text": "z. Refer to Section 9.1.5 for data collection after the clinical cutoff",
        "footnoteId": "fn_6",
        "structuredCondition": "data_collection.protocol == section_9.1.5 && event.date > clinical_cutoff.date",
        "appliesToActivityIds": [
          "Data collection"
        ],
        "sourceText": "z. Refer to Section 9.1.5 for data collection after the clinical cutoff"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Progression-Free Survival (PFS)",
        "endpointType": "Primary",
        "inputs": [
          "Date of randomization",
          "Date of first documented disease progression",
          "Date of death"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Until progression or death"
        },
        "algorithm": "min(Date of progression, Date of death) - Date of randomization",
        "successCriteria": "Statistically significant increase in PFS compared to control",
        "sourceText": "11.3.1. Primary Endpoint"
      },
      {
        "id": "ep_2",
        "name": "Secondary: Overall Response Rate (ORR)",
        "endpointType": "Secondary",
        "inputs": [
          "Complete Response (CR) status",
          "Partial Response (PR) status",
          "Total number of subjects"
        ],
        "timeWindow": {
          "reference": "Treatment Phase",
          "duration": "During study treatment"
        },
        "algorithm": "(Count of subjects with CR + Count of subjects with PR) / Total subjects",
        "successCriteria": "Proportion of subjects achieving CR or PR",
        "sourceText": "11.3.2. Secondary Endpoints"
      },
      {
        "id": "ep_3",
        "name": "Secondary: Overall Survival (OS)",
        "endpointType": "Secondary",
        "inputs": [
          "Date of randomization",
          "Date of death"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Until death"
        },
        "algorithm": "Date of death - Date of randomization",
        "successCriteria": "Statistically significant increase in OS compared to control",
        "sourceText": "11.3.2. Secondary Endpoints"
      },
      {
        "id": "ep_4",
        "name": "Secondary: Complete Response (CR) Rate",
        "endpointType": "Secondary",
        "inputs": [
          "Complete Response (CR) status",
          "Total number of subjects"
        ],
        "timeWindow": {
          "reference": "Treatment Phase",
          "duration": "During study treatment"
        },
        "algorithm": "Count of subjects with CR / Total subjects",
        "successCriteria": "Proportion of subjects achieving CR",
        "sourceText": "11.3.2. Secondary Endpoints"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Progression-Free Survival (PFS)",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Randomization",
          "Date of Disease Progression",
          "Date of Death"
        ],
        "derivationRule": "The time from the date of randomization until the date of the first documented PD or death from any cause, whichever comes first.",
        "baselineDefinition": "Date of Randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization until event or censoring",
        "imputationRule": "Censoring rules per protocol for subjects without event"
      },
      {
        "id": "dv_2",
        "name": "Overall Response Rate (ORR)",
        "variableType": "Categorical",
        "sourceVariables": [
          "Complete Response (CR)",
          "Partial Response (PR)"
        ],
        "derivationRule": "Proportion of subjects who achieve either a CR or PR as their best overall response.",
        "baselineDefinition": "Presence of measurable disease at screening",
        "baselineVisit": "Screening",
        "analysisWindow": "During treatment phase until disease progression",
        "imputationRule": "Subjects with no post-baseline assessment are considered non-responders"
      },
      {
        "id": "dv_3",
        "name": "Overall Survival (OS)",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Randomization",
          "Date of Death"
        ],
        "derivationRule": "The time from the date of randomization until the date of death from any cause.",
        "baselineDefinition": "Date of Randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization until death or last known alive date",
        "imputationRule": "Censored at the date the subject was last known to be alive"
      },
      {
        "id": "dv_4",
        "name": "Treatment Compliance (Ibrutinib/Placebo)",
        "variableType": "Custom",
        "sourceVariables": [
          "Total number of capsules dispensed",
          "Total number of capsules returned"
        ],
        "derivationRule": "(Total capsules taken / Total capsules expected to be taken) * 100",
        "baselineDefinition": "Not applicable",
        "baselineVisit": "Day 1",
        "analysisWindow": "Treatment Phase",
        "imputationRule": "None"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening Phase",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening Phase",
        "Treatment Phase (BR Treatment Period Cycles 1 to 6)",
        "Treatment Phase (R Treatment Every 2 cycles up to Cycle 30)",
        "Treatment Phase (After Cycle 30)",
        "End of Treatment Visit",
        "Posttreatment Follow-up Phase",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening Phase",
          "toState": "Treatment Phase (BR Treatment Period Cycles 1 to 6)",
          "trigger": "Progress to Treatment Phase (BR Treatment Period Cycles 1 to 6)"
        },
        {
          "fromState": "Treatment Phase (BR Treatment Period Cycles 1 to 6)",
          "toState": "Treatment Phase (R Treatment Every 2 cycles up to Cycle 30)",
          "trigger": "Progress to Treatment Phase (R Treatment Every 2 cycles up to Cycle 30)"
        },
        {
          "fromState": "Treatment Phase (R Treatment Every 2 cycles up to Cycle 30)",
          "toState": "Treatment Phase (After Cycle 30)",
          "trigger": "Progress to Treatment Phase (After Cycle 30)"
        },
        {
          "fromState": "Treatment Phase (After Cycle 30)",
          "toState": "End of Treatment Visit",
          "trigger": "Progress to End of Treatment Visit"
        },
        {
          "fromState": "End of Treatment Visit",
          "toState": "Posttreatment Follow-up Phase",
          "trigger": "Progress to Posttreatment Follow-up Phase"
        },
        {
          "fromState": "Treatment Phase (BR Treatment Period Cycles 1 to 6)",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "Treatment Phase (R Treatment Every 2 cycles up to Cycle 30)",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "Treatment Phase (After Cycle 30)",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "End of Treatment Visit",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "Posttreatment Follow-up Phase",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening Phase": "epoch_1",
        "Treatment Phase (BR Treatment Period Cycles 1 to 6)": "epoch_2",
        "Treatment Phase (R Treatment Every 2 cycles up to Cycle 30)": "epoch_3",
        "Treatment Phase (After Cycle 30)": "epoch_4",
        "End of Treatment Visit": "epoch_5",
        "Posttreatment Follow-up Phase": "epoch_6",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Rituximab",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 375.0,
            "unit": "mg"
          },
          {
            "amount": 560.0,
            "unit": "mg"
          },
          {
            "amount": 90.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "2 Day",
        "sourceText": "rogressive Disease Survival Follow- upaa Study Day Procedures and Assessmentsa Day -30 to randomizationb Day 1c Day 2 Day 1 Day 1 Within 30 days after last dose Drug Administration (see Table 2) Ritux"
      },
      {
        "id": "dosing_2",
        "treatmentName": "Bendamustine hydrochloride",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 90.0,
            "unit": "mg"
          },
          {
            "amount": 560.0,
            "unit": "mg"
          },
          {
            "amount": 375.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "2 Day",
        "sourceText": "Follow- upaa Study Day Procedures and Assessmentsa Day -30 to randomizationb Day 1c Day 2 Day 1 Day 1 Within 30 days after last dose Drug Administration (see Table 2) Rituximab 375 mg/m2  Xe,f Bendamu"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "Ibrutinib (PCI-32765)",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "durationDescription": "Until disease progression or unacceptable toxicity",
        "doseModifications": [
          "Dose modifications for toxicity are referenced in Section 6.4"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Placebo",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "durationDescription": "Until disease progression or unacceptable toxicity"
      },
      {
        "id": "dosing_llm_3",
        "treatmentName": "Bendamustine",
        "frequency": "Q4W",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "6 cycles",
        "doseModifications": [
          "Dose modifications for toxicity are referenced in Section 6.4.1"
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_1",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "sourceText": "Screening Phase ........................................................................................................................ 63 9.1.3. Treatment Phase ....................................."
      },
      {
        "id": "visit_3",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "Positron Emission Tomography (PET Scan)........................................................................... 67 9.2.1.3. Bone Marrow Assessment..................................................."
      },
      {
        "id": "visit_4",
        "visitName": "Baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "Baseline Assessments................................................................................................................ 82 11.4. Patient-reported Outcomes................................."
      },
      {
        "id": "visit_7",
        "visitName": "end of study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "the end of study. The timeframe for collection data on concomitant medications and adverse events, and study assessment and procedures now"
      },
      {
        "id": "visit_8",
        "visitName": "End of Treatment",
        "targetDay": null,
        "windowBefore": 30,
        "windowAfter": 30,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "An End of Treatment Visit will be scheduled within 30 days after the last dose of the last study treatment. The investigator is responsible for ensuring that all study"
      },
      {
        "id": "visit_llm_1",
        "visitName": "Screening Phase",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening Phase"
      },
      {
        "id": "visit_llm_3",
        "visitName": "Posttreatment Follow-Up Phase",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "Posttreatment Follow-Up Phase"
      },
      {
        "id": "visit_6",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 14,
        "windowAfter": 14,
        "isRequired": true,
        "visitNumber": 8,
        "epoch": "Treatment Phase",
        "sourceText": "deleting the specific timeframe (“within 14 days prior to randomization”) for laboratory parameters. However, in error, the timeframe was not removed. Per this amendment, the timeframe has been delete"
      },
      {
        "id": "visit_9",
        "visitName": "Day 2",
        "targetDay": 2,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "sourceText": "Day 2 Day 1 Day 1"
      },
      {
        "id": "visit_2",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 10,
        "sourceText": "Posttreatment Follow-Up Phase................................................................................................. 65 9.1.5. Clinical Cutoffs..............................................."
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "",
      "centralRandomization": true,
      "sourceText": "JNJ-54179060  (ibrutinib)\nClinical Protocol PCI-32765MCL3002 - Amendment INT-7\n23\nApproved, Date: 19 December 2019\nRationale: The protocol has been revised to be consistent with the Statistical Analys"
    }
  }
}